Active Projects on the 3T Siemens Scanner as of December 2020.
Click on a researcher’s name to learn more.
Dr. Jiwon Oh | The Canadian Proactive Cohort Study for People Living with Multiple Sclerosis (CANPROCO) | Neurology |
Dr. Tom Schweizer | Athlete traumatic brain injury, concussion and fMRI | Neurology |
Dr. Jiwon Oh | Quantitative Spinal Cord MRI as a Biomarker of Treatment Response in MS: A Prospective Study | Neurology |
Dr. Tom Schweizer | Investigating driving performance and underlying neural networks of aging cohorts and individuals with mild cognitive impairment and Alzheimer's disease | Neurology |
Dr. Sakina Rizvi | A dimensional approach to evaluate reward processing in major depressive disorder before and after treatment with desveniafaxine | Neurology |
Dr. Tom Schweizer | Understanding how disorders of the brain affect driving abilities: An fMRI driving-simulator study | Neurology |
Dr. Sidney Kennedy | Identification of reward-based markers for risk of depression following mild traumatic brain injury | Neurology |
Dr. Sakina Rizvi | Identifying the neural basis of capability for suicide | Neurology |
Dr. Jiwon Oh | Quantitative Spinal Cord MRI in Radiologically Isolated Syndrome: A Prospective Study | Neurology |
Dr. Sakina Rizvi | Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality | Neurology |
Dr. Iqwal Mangat | OCEAN trial: Optimal anticoagulation for enhanced risk patient path-catheter ablation for atrial fibrillation | Neurology |
Dr. Vinod Chandran (UHN) | Identifying Biomarkers for Joint Damage in Early Psoriatic Arthritis | Muskuloskeletal |
Dr. Kim Connelly | MAGMA study: Mineralocorticoid receptor antagonism clinical evaluation in atherosclerosis | Cardiology |
Dr. Anish Kirpalani | A pilot study to access the role of magnetic resonance imaging in assessing kidney transplant injury following kidney transplantation | Nephrology |
Dr. Anish Kirpalani | Functional Evaluation of Transplanted Kidneys in Outpatient Setting with Diffusion Weighted Magnetic Resonance Imaging and MR Elastography | Nephrology |
Dr. Anish Kirpalani | OPTIMUM MRI PROTOCOL: Magnetic Resonance Imaging in Volunteers to Establish Optimum Protocols | Body |
Dr. David Jenkins | MRI Enhanced dietary portfolio, exercise and heart risk | Body, Cardiology |
Jefferson Wilson | Natural History of Mild Degenerative Cervical Myelopathy: an observational study | Neurology |
Dr. Kim Connelly | Randomized double blind placebo controlled trial of Statins for the Primary Prevention of Heart Failure in patients wit cancer recieving anthracycline base chemotherapy - Pilot Study | Cardiology |
Mohammed Al-omran | Study of Lipids Inside the Carotid with Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology prior to Carotid End Arterectomy | Neurology |
John Graham | SPYRAL PIVOTAL | Body |
Dr. Lisa Hicks | An Open-Label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), a Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis | Body |
Jerry Teitel | Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (BeneGene-2) | Muskuloskeletal |
Dr. Sunit Das | Advanced MRI to Detect Stem cell Niches in Glioblastoma | Neurology |
Daniel Selchen | Multiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Progressive Forms of Multiple Sclerosis | Neurology |
Daniel Selchen | Multiple Sclerosis: Safety and Efficacy Study of Elezanumab (ABT-555) in Relapsing Forms of Multiple Sclerosis | Neurology |
Daniel Selchen | A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects with Relapsing-Remitting Multiple Sclerosis Switching from Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment | Neurology |
Dr. Magdy Elkhashab | A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis | Hepatology |
Dr. Magdy Elkhashab | A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-316 (resmetirom) in Patients with Non-Alcoholic Streatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation | Hepatology |
Dr. Magdy Elkhashab | A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (TANDEM) | Hepatology |
Dr. Magdy Elkhashab | A Phase 2, randomized, double-blind, double dummy, placebo-controlled, dose-ranging, dose-finding, parellel group study to assess efficacy and safety of PF-06865571 (OGAT21) alone and when coadministered with PF-05221304 (ACCI) in adult participants with biopsy-confirmed nonalcoholic steatohepatitis and fibrosis stage 2 or 3 | Hepatology |